Eli Lilly Hits a Record High as Retatrutide's Phase 3 Data Lands at the ADA

The Catalyst: Retatrutide Clears Its Own Franchise

The move is a pipeline print. On June 6, Lilly dropped pivotal Phase 3 data for retatrutide — its GLP-1/GIP/glucagon triple-agonist — at the ADA's 86th Scientific Sessions, and the numbers are the kind that re-rate a company.

In TRIUMPH-1, which enrolled 2,339 adults with obesity or overweight, the top dose produced an average of 70.3 lbs lost — 28.3% of body weight — over 80 weeks, climbing to 30.3% in patients starting at BMI ≥35. That edges out Zepbound, Lilly's own blockbuster, in a head-to-head against the standard the company itself set. More important for the addressable market: retatrutide cut knee osteoarthritis pain by 73% and reduced moderate-to-severe sleep apnea severity by 60%, turning a weight drug into a comorbidity drug with multiple reimbursable indications.

The companion diabetes trial, TRANSCEND-T2D-1, lowered A1C by up to 2.0% and weight by 36.6 lbs (16.8%) at 40 weeks and was published simultaneously in The Lancet. Seven more Phase 3 retatrutide readouts are still queued for 2026 — so the market is pricing a franchise it hasn't fully seen yet.

The Access Engine Nobody Tweets About

Efficacy data alone doesn't move a trillion-dollar stock 11% — it's efficacy plus the plumbing to get paid. A week before the ADA, CVS Caremark restored coverage of Zepbound and added Lilly's new oral pill Foundayo to its standard commercial formulary, with Foundayo live June 1 and Zepbound coverage resuming by October 1.

That was the last domino. With CVS Caremark, Express Scripts, and OptumRx all on board, all three of the largest U.S. pharmacy benefit managers now cover Lilly's obesity portfolio. Eligible commercial patients can pay as little as $25 a month, across a formulary template reaching an estimated 25–30 million Americans. So when retatrutide data hits, the read-through isn't 'great science, unclear commercialization' — it's a company that has already solved the reimbursement bottleneck for the prior generation and is now stacking a more potent molecule on top of working distribution.

Reading the Tape

LLY is now trading around $1,226, a fresh all-time high that puts market cap in the neighborhood of $1.1 trillion. The stock had been the rare mega-cap stuck negative on the year through March amid HSBC's bear case on obesity-market sizing; this two-week run — PBM access into ADA data — flipped that narrative hard.

On Hyperliquid, LLY trades as a HIP-3 perpetual that settles against the underlying equity via oracle pricing, which is why a 10.88% move shows up here despite only ~$3.5M of 24h volume on this specific market — the price is tracking the real share, not thin local order flow. For perp traders, that means the relevant risk calendar is Lilly's, not the order book's: the seven remaining retatrutide Phase 3 readouts, any safety signal (a dysesthesia signal at higher doses has been the watch item), and quarterly prints. Each has historically been a 5–10% session for LLY, and at up to 10x that magnitude compounds fast in both directions.